

CONTENTS

ARTICLES

THE MODERN EVOLUTION OF U.S. COMPETITION POLICY
ENFORCEMENT NORMS 377
William E. Kovacic

COMPETITION LAW FOR STATE-OWNED ENTERPRISES 479
David E.M. Sappington and J. Gregory Sidak

VERTICAL AGREEMENTS AND ARTICLE 81(1) EC:
THE EVOLVING ROLE OF ECONOMIC ANALYSIS 525
Vincent Verouden

SYMPOSIUM: ANTITRUST ISSUES IN THE
PHARMACEUTICAL INDUSTRY

EDITOR'S NOTE 577
Jonathan Ian Gleklen

THE HATCH-WAXMAN ACT: HISTORY, STRUCTURE,
AND LEGACY 585
Elizabeth Stotland Weiswasser and Scott D. Danzis

APPLYING THE NOERR DOCTRINE TO PHARMACEUTICAL PATENT
LITIGATION SETTLEMENTS 609
Mark L. Kovner, Colin R. Kass, and Avery W. Gardiner

PRODUCT MARKET DEFINITION IN THE PHARMACEUTICAL
INDUSTRY 633
M. Howard Morse

INNOVATION MARKETS AND MERGER ENFORCEMENT:
CURRENT PRACTICE IN PERSPECTIVE 677
Ronald W. Davis

AFTERWORD: SOME FURTHER OBSERVATIONS ON THE
"PHARMACEUTICAL WARS" 705
Stephen A. Stack, Jr.

